Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review

Cancer Communications

Auré¹  lien Simon¹  Hampig Raphael Kourie¹ 

[1] Jules Bordet Institute, Free University of Brussels, Brussels, Belgium

关键词: Metastatic melanoma;    Chemotherapy;    Immunotherapy;    Checkpoint inhibitors;    Vemurafenib;    ATM mutation;    Chemosensitivity;   

DOI  :  10.1186/s40880-017-0179-6

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, even in the absence of a response to modern targeted therapies and immunotherapies; accordingly, determining predictive biomarkers of the response to chemotherapies for metastatic melanoma remains a priority to guide treatment in these patients. We report a case study of a patient with B-Raf proto-oncogene serine/threonine kinase-mutated metastatic melanoma harbouring many genetic mutations. The patient did not respond to prior targeted therapies or immunotherapies but experienced a dramatic objective radiological and clinical response to subsequent dacarbazine-based chemotherapy. In the era of targeted therapies and immunotherapies for metastatic melanoma, cytotoxic chemotherapies may still represent an interesting therapeutic weapon in a well-defined subgroup of patients presenting with specific genetic and molecular features.

【 授权许可】

CC BY